News & Updates
Filter by Specialty:
Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma
Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.
Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma
15 May 2023
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
15 May 2023
Chronic pancreatitis not linked to adverse pregnancy outcomes
No association exists between chronic pancreatitis (CP) and adverse pregnancy outcomes, reports a study, noting a trend toward improvement in the clinical symptoms because of CP during pregnancy.
Chronic pancreatitis not linked to adverse pregnancy outcomes
14 May 2023
Vigorous hydration prevents post-ERCP pancreatitis
Vigorous periprocedural hydration (vHR) appears to be as effective as postprocedure per-rectal indomethacin for the prevention of postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), a study has shown.
Vigorous hydration prevents post-ERCP pancreatitis
13 May 2023
Weight gain persists, obesity rises in children after pandemic lockdown
Some children, particularly boys, continue to gain weight even after COVID-19 pandemic lockdown measures have been eased, indicating the challenges in reversing the effects of lockdowns, reveals a study in Argentina. However, sedentary behaviours have decreased while quality of life has improved.